1. Pfizer says late-stage coronavirus vaccine study shows moderate side effects  PharmaLive
  2. Pfizer says coronavirus vaccine study shows mostly mild-to-moderate side effects  Deccan Herald
  3. Coronavirus vaccine: Americans could get COVID-19 vaccine by end of 2020: Pfizer CEO  Yahoo Finance
  4. BioNTech, CureVac bag $745M in German funding for COVID-19 vaccine hopefuls  FiercePharma
  5. BioNTech shares jump premarket on news of 375 million euros in German funding for COVID-19 vaccine  MarketWatch
  6. View Full coverage on Google News
Pfizer Inc. said participants were showing mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.

Pfizer says late-stage coronavirus vaccine study shows moderate side effects – PharmaLive

Pfizer has said that Phase III trial participants were experiencing mild-to-moderate side effects with its investigational Covid-19 vaccine candidate.Pfizer has said that Phase III trial participants were experiencing mild-to-moderate side effects with its investigational Covid-19 vaccine candidate.

Pfizer says Covid-19 vaccine showed moderate side effects

Two German biotechs, BioNTech and CureVac, have been at the cutting edge of the hunt for a COVID-19 vaccine—a time consuming and costly process. In order to get both over the finish line, the German government is making a big down payment in both candidates' development.Two German biotechs, BioNTech and CureVac, have been at the cutting edge of the hunt for a COVID-19 vaccine—a time consuming and costly process. In order to get both over the finish line, the German government is making a big down payment in both candidates' development.

BioNTech, CureVac bag $745M in German funding for COVID-19 vaccine hopefuls | FiercePharma

Reuters with a curious report - Pfizer has more than 29,000 people in its 44,000-volunteer trial - testing their experimental COVID-19 vaccine What? for (not very much) more By Eamonn SheridanReuters with a curious report - Pfizer has more than 29,000 people in its 44,000-volunteer trial - testing their experimental COVID-19 vaccine What? for (not very much) more

Pfizer trial participants showing side effects when given either experimental coronavirus vaccine or placebo

Pfizer expects to have data next month on how well its COVID-19 candidate vaccine is protecting people against the coronavirus.Pfizer expects to have data next month on how well its COVID-19 candidate vaccine is protecting people against the coronavirus.

COVID-19 vaccine: Pfizer offers a positive update on its candidate

Albert Bourla, the CEO of Pfizer, said on Sunday morning that his company's trial of 30,000 people given a COVID vaccination was progressing well and he was optimistic.Albert Bourla, the CEO of Pfizer, said on Sunday morning that his company's trial of 30,000 people given a COVID vaccination was progressing well and he was optimistic.

Pfizer CEO says they could know if coronavirus vaccine works by the end of October | Daily Mail Online

Drugmaker Pfizer could know before the November election whether its coronavirus vaccine is safe and effective.Drugmaker Pfizer could know before the November election whether its coronavirus vaccine is safe and effective.

Pfizer COVID-19 vaccine may be ready for approval by October, CEO says

Pfizer chose not to take U.S. taxpayer money to help fund its coronavirus vaccine development, a move that CBS News' Margaret Brennan pointed out on Sunday is a bit of a financial risk for the pharmaceutical giant.CEO Albert Bourla admitted that it will indeed "be painful" if the vaccinePfizer chose not to take U.S. taxpayer money to help fund its coronavirus vaccine development, a move that CBS News' Margaret Brennan pointed out on Sunday is a bit of a financial risk for the pharmaceutical giant.CEO Albert Bourla admitted that it will indeed "be painful" if the vaccine

Pfizer CEO: Company refused taxpayer money for COVID-19 vaccine development to 'liberate our scientists'

Bloomberg - Are you a robot?

Pfizer Inc said on Tuesday participants were showing mostly mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study. The company said in a presentation to investors that side effects included fatigue, headache, chills and muscle pain. Some participants in the trial also developed fevers -Pfizer Inc said on Tuesday participants were showing mostly mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.

Pfizer says coronavirus vaccine study shows mostly mild-to-moderate side effects | Deccan Herald

On Monday, Pfizer began a two-day investor presentation to show how it will become a growth stock.On Monday, Pfizer began a two-day investor presentation to show how it will become a growth stock.

Pfizer Highlights Dozens of Drugs in Its Pipeline. Here’s What It Means for the Stock. | Barron's

BioNTech SE shares undefined soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in...BioNTech SE shares undefined soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in...

BioNTech shares jump premarket on news of 375 million euros in German funding for COVID-19 vaccine - MarketWatch

Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.

Germany grants BioNTech, CureVac $745 million to speed up COVID-19 vaccine work | Reuters

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

Pfizer Phase 3 Coronavirus Vaccine Data Slated For October

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.

Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development | The Motley Fool

The head of German vaccine regulator today said it won't be less thorough when evaluating covid-19 vaccine applications.The head of German vaccine regulator today said it won't be less thorough when evaluating covid-19 vaccine applications.

Germany says covid vaccine approvals could come by end of this year

Pfizer expects “conclusive data” by October-end and promised to make public all its safety and efficacy data in case of emergency authorisation for vaccinePfizer expects “conclusive data” by October-end and promised to make public all its safety and efficacy data in case of emergency authorisation for vaccine

Pfizer’s COVID-19 vaccine update | Candidate’s trial report finds no major safety issues

Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.

Pfizer stock rockets as potential COVID-19 vaccine delivery by end of 2020

Approval of a vaccine, however, will depend on federal regulators, Albert Bourla said.

Pfizer CEO says company will know if vaccine works by end of October

BERLIN: German biotech firm BioNTech said on Tuesday (Sep 15) it had secured almost US$450 million in government funding to speed up work on its ...BERLIN: German biotech firm BioNTech said on Tuesday (Sep 15) it had secured almost US$450 million in government funding to speed up work on its ...

BioNTech wins US$445 million German grant for COVID-19 vaccine - CNA

There is progress toward a COVID-19 vaccine.There is progress toward a COVID-19 vaccine.

404 Not Found

Pfizer and BioNTech’s vaccine is one of 35 potential inoculations currently in some phase of clinical testing, according to the WHO.Pfizer and BioNTech’s vaccine is one of 35 potential inoculations currently in some phase of clinical testing, according to the WHO.

Pfizer could have a vaccine ready by end of the year, says CEO Albert Bourla

NEW YORK • Pfizer said on Monday it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental Covid-19 vaccine it is developing with German partner BioNTech.. Read more at straitstimes.com.United States News -NEW YORK • Pfizer said on Monday it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental Covid-19 vaccine it is developing with German

Over 29,000 enrolled in Pfizer's Covid-19 vaccine trial, United States News & Top Stories - The Straits Times

Fox News medical contributor Dr. Marc Siegel said Monday that the common flu, unlike coronavirus, is a "moving target" that often changes form from year to year, while COVID is more static in that regard.Fox News medical contributor Dr. Marc Siegel said Monday that the common flu, unlike coronavirus, is a "moving target" that often changes form from year to year, while COVID is more static in that regard.

Pfizer’s CEO says the pharmaceutical giant should know how effective its experimental COVID-19 vaccine will be by the end of October.Pfizer’s CEO says the pharmaceutical giant should know how effective its experimental COVID-19 vaccine will be by the end of October.

Pfizer CEO expects vaccine trial results before November | WOODTV.com

Pfizer's RNA-based Covid-19 vaccine candidate BNT162b2 which is being developed in partnership with BioNTech is set to enter Phase 3 human trials.

Coronavirus USA: When could Pfizer's vaccine start shipping? - AS.com

In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October. In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.

Pfizer, BioNTech Say COVID-19 Vaccine Might Be Ready by End of October | BioSpace

Pfizer CEO Albert Bourla to CBS: Will know coronavirus vaccine status by OctoberAlbert Bourla, the head of pharmaceutical giant Pfizer, which is among the companies developing a coronavirus vaccine, said that there is a 'good chance' the company will know whether its vaccine works by the end of October.

Pfizer CEO Albert Bourla to CBS: Will know coronavirus vaccine status by October | World News – India TV

Pfizer Inc.’s $48 billion gain in market value since late March, egged on by optimism for a successful Covid-19 vaccine, may soon hit a wall.

Pfizer poised for drop after US$48B climb on COVID vaccine - BNN Bloomberg

Pfizer CEO, Albert Boula, has said the drug company could release a coronavirus vaccine before the year is out if approved by the FDA.Pfizer CEO, Albert Boula, has said the drug company could release a coronavirus vaccine before the year is out if approved by the FDA.

Pfizer could have working Covid-19 vaccine before the end of 2020 | Buzz.ie

GROTON, CT (WFSB) - The race to find a COVID-19 vaccine continues.GROTON, CT (WFSB) - The race to find a COVID-19 vaccine continues.

Pfizer aims to learn if its COVID-19 vaccine works by the end of October | News | wfsb.com

CBS host Brennan wanted Bourla to say for the record that there is zero chance Americans can get a vaccine shot by the end of the year, but he would not say it.CBS host Brennan wanted Bourla to say for the record that there is zero chance Americans can get a vaccine shot by the end of the year, but he would not say it.

Pfizer CEO: We'll Know if Vaccine Works By End of October

Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.

Pfizer should know if COVID vaccine works by end of October

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration ...Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration approval to expand the late-...

Pfizer, Inc. (NYSE:PFE), Astrazeneca PLC (NYSE:AZN) - Pfizer Seeks FDA Nod To Expand Late-Stage COVID-19 Vaccine Trial | Benzinga

Pfizer CEO announced that the company's COVID-19 vaccine may be ready by the year-end if things go well while adding that it is already being mass-produced.Pfizer CEO announced that the company's COVID-19 vaccine may be ready by the year-end if things go well while adding that it is already being mass-produced.

COVID-19 vaccine manufacturing has begun at a risk, will be ready by year-end: Pfizer CEO - Republic World

A conclusive result on the efficacy of the vaccine is likely by the end of OctoberA conclusive result on the efficacy of the vaccine is likely by the end of October

Pfizer, BioNTech to expand COVID-19 vaccine Phase 3 trial | Americas – Gulf News

Breaking News, Latest News and Current News from OANN.com. Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.

Pfizer says their vaccine will likely be approved by end of year | One America News Network

"We have already manufactured hundreds of thousands of doses," Pfizer head Albert Bourla said."We have already manufactured hundreds of thousands of doses," Pfizer head Albert Bourla said.

Pfizer Has COVID-19 Vaccine In Production, Says Rejecting Federal Funding Gave Scientists Freedom

Pfizer and BioNTech reiterated that results from their vaccine candidate's late-stage trial could be available as early as October.Pfizer and BioNTech reiterated that results from their vaccine candidate's late-stage trial could be available as early as October.

The race for a coronavirus vaccine shows no signs of slowing as more companies move their vaccine candidates through clinical trials, growing closer to determining which will be considered safe and effective.The race for a coronavirus vaccine shows no signs of slowing as more companies move their vaccine candidates through clinical trials, growing closer to determining which will be considered safe and effective.

Pfizer proposes expanding Covid-19 vaccine trial to include more diversity as race for a vaccine continues :: WRAL.com

Access Denied

The company has already manufactured hundreds of thousands of doses in anticipation.The company has already manufactured hundreds of thousands of doses in anticipation.

Pfizer preparing to distribute COVID vaccine by year-end, CEO says - Axios

Pfizer, along with Moderna and AstraZeneca, is one of three companies currently in late-stage testing for a novel coronavirus vaccine.Pfizer, along with Moderna and AstraZeneca, is one of three companies currently in late-stage testing for a novel coronavirus vaccine.

Coronavirus: Pfizer vaccine could be distributed by year’s end, CEO says